1. Some manufacturers reported inaccurate drug product data to CMS Publication: [Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, September 2020 Subject(s): Data AccuracyDrug Industry -- legislation & jurisprudenceGovernment RegulationMedicare Part B -- economicsPharmaceutical Preparations -- economicsUnited StatesUnited States. Department of Health and Human Services
2. Medicare Part B drug payments: impact of price substitutions based on 2019 average sales prices Publication: Washington, D.C. : U.S. Department of Health and Human Services, Office of Inspector General, June 2021 Subject(s): Government RegulationMedicare Part B -- economicsPharmaceutical Preparations -- economicsUnited StatesUnited States. Department of Health and Human Services
